Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10467315 | 0.85 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL28621894 | 0.82 | POLB (0.48) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29123401 | 0.77 | POLB (0.44) | KDM4EHSD17B10KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27680089 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL17616023 | 0.77 | GPR3 (0.52) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL2184283 | 0.77 | KDM4E (0.52) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL28836465 | 0.76 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10GLA | |
| SCHEMBL10467337 | 0.75 | TRPM8 (0.47) | ALDH1A1CYP2C19KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL10776104 | 0.75 | TRPM8 (0.47) | ALDH1A1CYP2C19KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL28836488 | 0.75 | KDM4E (0.49) | KDM4EALDH1A1HPGDHSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| EP-4321523-A2 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-14 | — | — | EP | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| CN-113412271-A | Hamiltrin derivatives having cysteine residue | 大日本住友制药株式会社 | 2021-09-17 | — | — | CN | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3666788-A1 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-111051329-A | Hamiltrin derivatives and antibody drug complexes thereof | 大日本住友制药株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-111032676-A | Antibody drug complex comprising a hemiasterlin derivative | 大日本住友制药株式会社 | 2020-04-17 | — | — | CN | disclosed |
| CN-104125956-A | Cyclic amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase and uses thereof | CONNEXIOS LIFE SCIENCES PVT LTD | 2014-10-29 | — | — | CN | disclosed |
| CN-104125960-A | Derivatives of aza adamantane and uses thereof | CONNEXIOS LIFE SCIENCES PVT LTD | 2014-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | KDM4E 785/4885ALDH1A1 24/4885HPGD 4801/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | KDM4E 574/4885ALDH1A1 1215/4885HPGD 2797/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | KDM4E 574/4885ALDH1A1 1215/4885HPGD 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.